Cardiac Marker Testing Market Poised for Steady Growth, Driven by Point-of-Care Expansion

ARLINGTON, Va., June 18, 2025 /PRNewswire/ -- The global cardiac marker testing market is on track for sustained growth, according to research from Kalorama Information's IVD Business Outlook. As cardiovascular disease remains a leading cause of mortality worldwide, demand for rapid and accurate diagnostic testing continues to rise.

Kalorama's latest analysis highlights that while traditional lab-based cardiac marker testing remains the dominant segment, the point-of-care (POC) segment is gaining ground at a faster pace—reflecting growing interest in decentralized and near-patient diagnostics. The article projects continued market expansion through 2029, supported by adoption of high-sensitivity assays and increasing procedure volumes globally.

"The shift toward point-of-care cardiac testing reflects a broader transformation in healthcare delivery," said Daniel Granderson, Senior Editor of Kalorama Information. "Providers are seeking faster diagnostic tools that enable quicker clinical decisions, especially in emergency and acute care settings."

Cardiac biomarkers such as troponin, BNP, CK-MB, and myoglobin remain central to acute care diagnostics, accounting for the vast majority of test volumes. North America and Europe collectively account for more than three-quarters of global market share, while the Asia Pacific region continues to emerge as a high-potential growth area.

The article also profiles major players shaping the market landscape, including Danaher (via Beckman Coulter and Radiometer), Siemens Healthineers, QuidelOrtho, Roche, and Abbott. Recent product launches, regulatory approvals, and shifts in diagnostic testing demand—particularly post-pandemic—are helping to reshape vendor dynamics and innovation priorities.

For more insights on market forecasts, regional dynamics, and comprehensive market views, visit Kalorama Information's IVD Business Outlook.

About IVD Business Outlook
In Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market.

About Kalorama Information
Kalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide.

SOURCE Kalorama Information